You are here
The Inter-rater reliability study final report was approved by the Pricing Authority in April 2017. The primary aims of the study were to test the inter-rater reliability of the mental health phase of care instrument, gather information about the clinicians' views of the mental health phase of care, identifying ways of increasing the clarity to reduce the ambiguity of the instrument, and to provide recommendations on how the instrument may be refined.
The non-admitted study was comprehensive across a range of settings (e.g. outpatients, community and satellite clinics). Similarly all service streams were included regardless of funding source. This ensured that all services were accounted for and costed appropriately providing an accurate cost of delivering multiple services across multiple settings (e.g. overhead costs are apportioned across all patients).
The costing study on home delivered dialysis was undertaken in 2014. The purpose of the study was to collate and compare the range of costing studies and economic evaluations that have been carried out on these services over the past decade.
The report identifies two key studies - NSW Dialysis Costing Study, conducted in 2008, and Queensland Health Renal Replacement Therapy Costing Study, conducted in 2008 - which are useful in estimating the current costs of home-based dialysis.
PwC and its sub-contractor The Independent Hospital Pricing Authority (IHPA) engaged PwC and its sub-contractor SyRis Consulting to undertake a review and costing study of Australian radiotherapy services. The study was commissioned to determine the reliability of radiotherapy cost data due to its role in the development of associated price weights in both admitted and non-admitted settings.